Q-omics provides the consensus-scored FAM183BP profile across patient tissues and cancer cell-line models. FAM183BP expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, FAM183BP is differentially expressed in 7, with the highest sampling consensus in KIRP. Additionally, FAM183BP RNA expression shows 11,039 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, KIRP, and TGCT as cancer lineages where FAM183BP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM183BP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM183BP survival associations across molecular data types. FAM183BP RNA expression shows survival associations in the most cancer types (25), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM183BP RNA expression–survival associations across cancer types. High FAM183BP expression shows unfavorable associations in UVM, KIRC, COAD and THYM, but favorable associations in ESCA and SKCM. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for FAM183BP RNA expression.
This table summarizes FAM183BP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for FAM183BP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM183BP shows lower tumor expression in KIRP, LUSC and LUAD and higher tumor expression in HNSC, STAD and CHOL. The KIRP box plot shows higher FAM183BP RNA expression in normal versus tumor tissue (log2 FC = −0.106, t-test p = .001).
This table shows molecular features associated with FAM183BP in patient tissues and cancer cell lines. In patient samples, FAM183BP shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM183BP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE.
